Optimal antiPlatelet Therapy for High Bleeding and Ischemic RISK Patients Trial
Status:
Recruiting
Trial end date:
2021-09-30
Target enrollment:
Participant gender:
Summary
Current guidelines recommend that patients with ACS undergoing stent implantation might be
offered extended DAPT treatment for up to 30 months if necessary.
Therefore, we designed a prospective, multicenter, randomized, placebo-controlled trial among
ACS patients with high-risk on ischemic and bleeding who received a new generation of DES and
received 9 to 12 months of DAPT, and evaluated whether clopidogrel monotherapy reduce the
risk of bleeding compared with clopidogrel plus ASA in the following 9 months and achieved
non-inferior outcomes in preventing ischemic risk.